Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

APhA on natural products

This article was originally published in The Tan Sheet

Executive Summary

Natural Products: A Case-Based Approach for Health Care Professionals has been published by the American Pharmacists Association in order to "help health care practitioners evaluate natural products used in treating 14 common conditions," the association announces April 19. The book is authored by APhA member Karen Shapiro, Department of Medicine, Rancho Los Amigos National Rehabilitation Center, Los Angeles. The publication devotes one chapter to each of the 14 common conditions, which include migraine, osteoarthritis, erectile dysfunction, cholesterol reduction, cardiovascular disease, flu, weight loss and performance enhancement. It discusses commonly used natural products as well as their dosages and effects, and provides "extensive references demonstrating the scientific evidence for use or avoidance of each product," APhA states. Dialogue suggestions about safety considerations and drug interactions also are included. The book can be purchased through APhA by phone or through the group's website...

You may also be interested in...



Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel